AIDS TREATMENT NEWS Issue #351, September 22, 2000
John S. James
Several important AIDS-related conferences took place in September 2000, and expert summaries are now available for at least three of them. Reports are still being written as we go to press; the topics listed below are only a selection to show the range of information available.
[Note: In this article we are using Web addresses as subtitles.]
** ICAAC (The 40th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy), Toronto, Sept. 17-20
http://hiv.medscape.com
Medscape has ICAAC coverage on resistance and replication; benefits of antiretroviral therapy vs. risk of cardiac disease; switching antiretrovirals; use of immunologic and virologic measurements; drug levels and clinical implications; treatment interruptions; when to start HAART; new antiretrovirals; IL-2; efavirenz interactions; Kaletra; immune reconstitution with HAART, and other topics. More than 20 CME-accredited articles based in part on the conference will be posted later.
Note: This site requires registration the first time you use it, but the registration is free.
http://www.thebody.com
The Body includes ICAAC reports on pharmacoeconomics and epidemiology of antibiotic use; drug-drug interactions; protease-sparing combinations; new antiretrovirals; adherence; primary HIV infection; viral co-infection with HIV; resistance testing; lipodystrophy and metabolic complications; strategies for switching antiretrovirals; changing epidemiology of HIV disease...
http://www.hivandhepatitis.com
HIV and Hepatitis.com includes switching from protease inhibitors to efavirenz or nevirapine; experimental treatments for hepatitis B; long-term data on efavirenz+d4T+3TC in treatment-naive patients... More reports are being written.
http://www.asmusa.org/mtgsrc/40icaac.htm
The official site for this ICAAC conference has searchable abstracts online. Use it to look for any drug, condition, author, etc. of interest. Note that all the abstracts except the late breakers were written months before the meeting.
** 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy, Toronto, Sept. 13-15
http://www.hivandhepatitis.com
HIV and Hepatitis.com includes articles on low dose human growth hormone treatment of body-fat changes; international cohort studies on prevalence and risk factors of lipodystrophy; the first randomized study of treatment for lipodystrophy "in which metformin therapy was shown to reduce both insulin resistance and intra-abdominal fat accumulation"; animal and human studies on pathogenesis of lipodystrophy; body composition measurements; glucose metabolism studies; vascular disease; bone disease; mitochondrial toxicity...
http://www.thebody.com
The Body includes physiology of lipodystrophy; mitochondrial studies; growth hormone treatment; a metabolic study of indinavir on healthy HIV-negative volunteers...
http://www.natap.org
NATAP (National AIDS Treatment Advocacy Project) includes human growth hormone studies and treatment; mitochondrial toxicity, including its measurement in sperm...
** IDSA (38th Annual Meeting of the Infectious Diseases Society of America), New Orleans, Sept. 7-10
http://www.thebody.com
The Body has a summary of each day by Keith Henry, M.D., covering a wide range of topics presented at the conference, with a clinical focus on practical information for physicians.
http://hiv.medscape.com
Medscape will have summaries of the IDSA conference, but they were not online as we went to press.
Additional Summaries
This listing is not complete, as more summaries will be added on these and other Web sites.
000922
ATN35104
Copyright © 2000 - AIDS Treatment News. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. AIDS Treatment News, Subscription and Editorial Office: 1233 Locust St., 5th floor Philadelphia, PA 19107 800/TREAT-1-2 toll-free email: aidsnews@critpath.org http://www.aidsnews.org
Subscription Information: Call 800/TREAT-1-2: Businesses, Institutions, Professionals: $270/year. Includes early delivery of an extra copy by email. Nonprofit organizations: $135/year. Includes early delivery of an extra copy by email. Individuals: $120/year, or $70 for six months. Special discount for persons with financial difficulties: $54/year, or $30 for six months. If you cannot afford a subscription, please write or call. Outside North, Central, or South America, add air mail postage: $20/year, $10 for six months. Back issues available. Fax subscriptions, bulk rates, and multiple subscriptions are available; contact our office for details. Please send U.S. funds: personal check or bank draft, international postal money order, or travelers checks. VISA, Mastercard, and purchase orders also accepted. ISSN # 1052-4207
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .